A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.